About Protein arginine N-methyltransferase 2
Protein arginine N-methyltransferase 2 (PRMT2) is a protein
from Homo sapiens identified by UniProt accession
P55345, 433 residues long.
MolForge cross-references it against 0 known binders and
54 disease associations.
Target properties
| Protein name | Protein arginine N-methyltransferase 2 |
| UniProt accession | P55345 |
| Gene | PRMT2 |
| Organism | Homo sapiens |
| Length | 433 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (54)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.08
- renal cell carcinoma · score 0.08
- acute myeloid leukemia · score 0.07
- monocyte percentage of leukocytes · score 0.07
- glioblastoma multiforme · score 0.07
- mean corpuscular volume · score 0.06
- atherosclerosis · score 0.06
- neoplasm · score 0.06
- t-tau:beta-amyloid 1-42 ratio measurement · score 0.06
- diabetes mellitus · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P55345-F1 | alphafold | PREDICTED | 91.86 | — |
Amino-acid sequence (433 residues)
MATSGDCPRS ESQGEEPAEC SEAGLLQEGV QPEEFVAIAD YAATDETQLS FLRGEKILIL RQTTADWWWG ERAGCCGYIP ANHVGKHVDE YDPEDTWQDE EYFGSYGTLK LHLEMLADQP RTTKYHSVIL QNKESLTDKV ILDVGCGTGI ISLFCAHYAR PRAVYAVEAS EMAQHTGQLV LQNGFADIIT VYQQKVEDVV LPEKVDVLVS EWMGTCLLFE FMIESILYAR DAWLKEDGVI WPTMAALHLV PCSADKDYRS KVLFWDNAYE FNLSALKSLA VKEFFSKPKY NHILKPEDCL SEPCTILQLD MRTVQISDLE TLRGELRFDI RKAGTLHGFT AWFSVHFQSL QEGQPPQVLS TGPFHPTTHW KQTLFMMDDP VPVHTGDVVT GSVVLQRNPV WRRHMSVALS WAVTSRQDPT SQKVGEKVFP IWR
Explore Protein arginine N-methyltransferase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets